All In Biotech

Drug Trial Radar · NCT04489108

Tranexamic Acid for Acute Upper Gastrointestinal Bleed in Cirrhosis

Tranexamic Acid for Acute Upper Gastrointestinal Bleed in Cirrhosis - A Randomized Placebo Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jan 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

600

Planned (sponsor's estimate)

Start

Nov 5, 2020

Primary completion

Apr 30, 2022

Study completion Apr 30, 2022

Sponsor

Lead sponsor
Institute of Liver and Biliary Sciences, IndiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The management of acute upper gastrointestinal bleeding (UGIB) is challenging in patients with cirrhosis, as it is responsible for severe complications and high mortality rates. Fibrinolytic activity of the epithelial surfaces and of the submucosal blood vessels may interfere with hematemesis and even delay healing of ulcers. Tranexamic acid (TXA) may help control the bleeding by counterbalancing cirrhosis-related hyperfibrinolysis. Still, there is a lack of unbiased data to conclude on its efficacy. Tranexamic Acid in patients with acute Upper Gastrointestinal bleed have been shown to prevent re bleed in few studies when combined with standard medical management (which generally comprises of initial fluid resuscitation, intravenous PPI , splanchnic vasoconstrictors, blood transfusions and coagulopathy corrections as per lab parameters) but no randomized placebo controlled trial has been done. The aim of this study is to evaluate the efficacy of TXA in the early treatment of acute UGIB as compared to placebo in patients with cirrhosis.

Conditions

  • Liver Cirrhosis

Interventions

  • Tranexamic acidDrug

    Tranexamic Acid 1g iv bolus as loading dose followed by 3g Tranexamic Acid infused over next 24 hours

  • Standard Medical TreatmentOther

    Standard Medical Treatment

  • PlaceboOther

    isotonic solution (saline)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients developing five-day treatment failure in both the groupsTime frame: 5 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Liver & Biliary Sciences

    New Delhi, National Capital Territory of Delhi, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.